Patents by Inventor Thomas Monath
Thomas Monath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181725Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: November 22, 2022Publication date: June 15, 2023Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Publication number: 20230086859Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: June 29, 2022Publication date: March 23, 2023Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 11554169Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: GrantFiled: September 20, 2018Date of Patent: January 17, 2023Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Patent number: 11407790Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: April 30, 2020Date of Patent: August 9, 2022Assignee: HOOKIPA BIOTECH GMBHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Publication number: 20220073568Abstract: The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection.Type: ApplicationFiled: November 24, 2021Publication date: March 10, 2022Inventors: Thomas Monath, Katherine Cohen, Vera Baumgartl-Strasser
-
Patent number: 11214598Abstract: The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection.Type: GrantFiled: November 3, 2016Date of Patent: January 4, 2022Assignee: Hookipa Biotech GmbHInventors: Thomas Monath, Katherine Cohen, Vera Baumgartl-Strasser
-
Publication number: 20210024584Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses.Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: April 30, 2020Publication date: January 28, 2021Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 10669315Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: GrantFiled: June 9, 2016Date of Patent: June 2, 2020Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Publication number: 20190247493Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: September 20, 2018Publication date: August 15, 2019Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Publication number: 20180319845Abstract: The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection.Type: ApplicationFiled: November 3, 2016Publication date: November 8, 2018Inventors: Thomas Monath, Katherine Cohen, Vera Baumgartl-Strasser
-
Patent number: 10111945Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: GrantFiled: December 3, 2014Date of Patent: October 30, 2018Assignee: Hookipa Biotech GmbHInventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Publication number: 20180179257Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.Type: ApplicationFiled: June 9, 2016Publication date: June 28, 2018Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
-
Patent number: 9848254Abstract: A content delivery network (CDN) includes: at least one CDN origin node; and multiple CDN cache nodes connected to the at least one CDN origin node via an optical transport network (OTN). Deliveries and/or routing from the multiple CDN cache nodes to the at least one CDN origin node and/or vice versa is performed below layer 3 of the Open Systems Interconnection (OSI) model.Type: GrantFiled: June 23, 2015Date of Patent: December 19, 2017Assignee: DEUTSCHE TELEKOM AGInventors: Ralf-Peter Braun, Michael Dueser, Thomas Monath
-
Publication number: 20160296619Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: December 3, 2014Publication date: October 13, 2016Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuelaö Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mülbacher
-
Publication number: 20150382088Abstract: A content delivery network (CDN) includes: at least one CDN origin node; and multiple CDN cache nodes connected to the at least one CDN origin node via an optical transport network (OTN). Deliveries and/or routing from the multiple CDN cache nodes to the at least one CDN origin node and/or vice versa is performed below layer 3 of the Open Systems Interconnection (OSI) model.Type: ApplicationFiled: June 23, 2015Publication date: December 31, 2015Inventors: Ralf-Peter Braun, Michael Dueser, Thomas Monath
-
Publication number: 20070275015Abstract: The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.Type: ApplicationFiled: November 17, 2003Publication date: November 29, 2007Inventors: Juan Arroyo, Charles Miller, John Catalan, Thomas Monath
-
Publication number: 20070269458Abstract: The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.Type: ApplicationFiled: October 19, 2005Publication date: November 22, 2007Applicant: Acambis Inc.Inventors: Farshad Guirakhoo, Jian Liu, John Catalan, Thomas Monath, Konstantin Pugachev
-
Publication number: 20070231336Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: May 30, 2007Publication date: October 4, 2007Applicant: Acambis Inc.Inventors: William Thomas, Paul Giannasca, Zhenxi Zhang, Wende Lei, Thomas Monath
-
Publication number: 20060153873Abstract: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.Type: ApplicationFiled: May 27, 2003Publication date: July 13, 2006Inventors: Richard Weltzin, Thomas Monath
-
Publication number: 20060029608Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: September 26, 2005Publication date: February 9, 2006Inventors: William Thomas, Paul Giannasca, Zhenxi Zhang, Wende Lei, Thomas Monath